Gw576484X

Gw576484X

SCHEMBL30467445

CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 17/20 1.00
ERBB2 P04626 15/20 1.00
ABCB11 O95342 2/20 0.83
MEN1 O00255 1/20 0.83
PIK3C2B O00750 1/20 0.83
MAP2K7 O14733 1/20 0.83
RIPK2 O43353 1/20 0.83
PIK3C2G O75747 1/20 0.83
STK10 O94804 1/20 0.83
ABL1 P00519 1/20 0.83
INSR P06213 1/20 0.83
RET P07949 1/20 0.83
CYP3A4 P08684 1/20 0.83
PDGFRB P09619 1/20 0.83
SRC P12931 1/20 0.83
CYP3A5 P20815 1/20 0.83
ERBB3 P21860 1/20 0.83
CDK2 P24941 1/20 0.83
KMT2A Q03164 1/20 0.83
KCNH2 Q12809 1/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gw576484X SCHEMBL2099115 1.00 EGFR (1.00) EGFRERBB2ABCB11MEN1PIK3C2B
SCHEMBL13332780 0.93 EGFR (1.00) EGFRERBB2ABCB11MEN1PIK3C2B
SCHEMBL5433703 0.92 EGFR (0.85) EGFRERBB2ABCB11MEN1PIK3C2B
SCHEMBL2101983 0.92 EGFR (0.87) EGFRERBB2ABCB11MEN1PIK3C2B
SCHEMBL15099362 0.92 EGFR (0.87) EGFRERBB2ABCB11MEN1PIK3C2B
SCHEMBL18211401 0.91 EGFR (0.86) EGFRERBB2ABCB11MEN1PIK3C2B
SCHEMBL13894728 0.91 EGFR (0.86) EGFRERBB2ABCB11MEN1PIK3C2B
SCHEMBL3324845 0.91 EGFR (0.83) EGFRERBB2ABCB11MEN1PIK3C2B
SCHEMBL2099750 0.91 EGFR (0.83) EGFRERBB2ABCB11MEN1PIK3C2B
SCHEMBL114306 0.91 EGFR (0.85) EGFRERBB2ABCB11MEN1PIK3C2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230190748-A1 COMPOSITIONS FOR TREATMENT OF AGED DISEASES GERO PTE LTD (SG) 2023-06-22 US claimed
US-20230190748-A1 COMPOSITIONS FOR TREATMENT OF AGED DISEASES GERO PTE LTD (SG) 2023-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230190748-A1 COMPOSITIONS FOR TREATMENT OF AGED DISEASES AGER, CKMT1A; CKMT1B, GLA EGFR 1153/4885ERBB2 1599/4885ABCB11 3874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.